bioRxiv · 10.64898/2026.06.26.734815
Genomic and Functional Insights into the Cluster V Mycobacteriophage ‘EniyanLRS’ and its therapeutically relevant LysB
Abstract
Multidrug-resistant tuberculosis and the rising burden of nontuberculous mycobacterial diseases demand innovative treatment strategies. Mycobacteriophages and endolysins offer promising therapeutic potential due to their targeted bacterial cell wall-damaging activity, vast diversity, and lack of antibiotic cross-resistance. Here, we report the genomic and functional characterisation of a V Cluster mycobacteriophage, EniyanLRS, and its endolysins. Some genomic features: genome size (78.53 kbp), a relatively low GC content (56.9%), a long Tape Measure Protein gene (5.97 kbp), and a high number of tRNAs (24), suggest distinct adaptation and translational efficiency of our phage. Phenotypically, EniyanLRS exhibits a siphovirus morphology, lytic life cycle and infects drug-resistant Mycobacterium fortuitum. While its endolysin LysA, harbouring a lysozyme-chitinase-amidase domain, showed moderate lysozyme-like activity without significant antibacterial activity, LysB, an /{beta}-hydrolase, exhibited superior in vitro esterase activity and showed pronounced cell wall disruption in M. smegmatis and M. fortuitum, along with considerable antibiofilm activity (62.77% and 41.91% inhibition, respectively). Collectively, our analysis reveals key functional properties of EniyanLRS phage and its LysB, demonstrating their suitability as effective biological candidates for mycobacterial therapy.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Nadar, K., Eniyan, K., Bajpai, U.. 2026-06-27. Genomic and Functional Insights into the Cluster V Mycobacteriophage ‘EniyanLRS’ and its therapeutically relevant LysB. https://doi.org/10.64898/2026.06.26.734815
Cite the original work for its findings. Save a collection to share your selection of sources.